Hanne Capital

Hanne Capital is a private equity firm specializing in the healthcare sector, with a particular emphasis on biotechnology and related industries. The firm focuses on early-stage and growth-stage investments, targeting companies in pharmaceuticals, medical devices, and innovative healthcare technologies.

Established in 2017, Hanne Capital has a track record of deploying over $350 million into a dozen companies, many of which have successfully listed on major stock exchanges in China, the United States, and Hong Kong, collectively achieving a market capitalization exceeding $6 billion. The firm's investment strategy centers on emerging technologies in immuno-oncology, including oncolytic viruses, single B-cell profiling-based monoclonal antibody discovery, tumor neoantigens, and therapeutic vaccines.

Hanne Capital's founding partners bring extensive experience from leading private equity funds and multinational pharmaceutical and medical device companies. Their expertise enables the firm to identify and support high-potential healthcare ventures, contributing to the advancement of medical treatments and technologies. The firm's portfolio reflects a commitment to fostering innovation and growth within the healthcare sector, aiming to deliver substantial returns while positively impacting global health outcomes.